LAVA Therapeutics N.V.
LVTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.34 | 0.02 | -0.02 |
| FCF Yield | -38.72% | 5.93% | -5.50% | -19.42% |
| EV / EBITDA | -1.07 | 1.73 | 1.35 | -2.16 |
| Quality | ||||
| ROIC | -13.38% | -11.50% | -11.54% | -15.31% |
| Gross Margin | 0.00% | 0.00% | -391.98% | 0.00% |
| Cash Conversion Ratio | 0.68 | 1.59 | 3.35 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.02% | -40.97% | -36.61% | -14.83% |
| Free Cash Flow Growth | -778.96% | 244.13% | 83.76% | -3.21% |
| Safety | ||||
| Net Debt / EBITDA | 3.08 | 13.04 | 9.56 | 1.87 |
| Interest Coverage | 0.00 | -58.82 | -13.78 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -16,065.00 | -1,278.50 | -9.98 | -1,195.05 |